Intelligence Platform

Patents

Browse 263 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10500229

Targeted disruption of the MHC cell receptor

Sangamo Therapeutics, Inc. · Granted Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10485879

Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA

Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health · Granted Tue Nov 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10414656

Discrete carbon nanotubes with targeted oxidation levels and formulations thereof

MOLECULAR REBAR DESIGN, LLC · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10401361

Intracellular organelle peptide targeted enzyme substrates

Marker Gene Technologies, Inc · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10376598

Targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370680

Method of treating factor IX deficiency using nuclease-mediated targeted integration

Sangamo Therapeutics, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10328109

Targeted adenoviruses and methods of making, isolating, and using

Regents of the University of Minnesota · Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10316316

Compositions for targeted delivery of siRNA

Arrowhead Pharmaceuticals, Inc. · Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10300113

Targeted therapeutic proteins

BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10301369

Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteins

BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10245322

Nanostructured carriers for guided and targeted on-demand substance delivery

The Regents of the University of California · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10232049

Targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10182984

Targeted interferons demonstrate potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10184004

CD47 targeted therapies for the treatment of infectious disease

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10155011

Targeted disruption of T cell receptor genes using engineered zinc finger protein nuclease

Sangamo Therapeutics, Inc. · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125171

Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof

Apellis Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10117944

Targeted therapeutics

Madrigal Pharmaceuticals, Inc. · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10113207

Methods and compositions for targeted single-stranded cleavage and targeted integration

Sangamo Therapeutics, Inc. · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10111926

Selectively targeted antimicrobial peptides and the use thereof

The Regents of the University of California · Granted Tue Oct 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10046057

Methods for arranging and packing nucleic acids for unusual resistance to nucleases and ta

The Regents of the University of California · Granted Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10034919

Targeted human-interferon fusion proteins

Universite Montepellier 2 · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10035822

Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and me

Apellis Pharmaceuticals, Inc. · Granted Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10029017

Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug

The Regents of the University of California · Granted Tue Jul 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9993553

Methods and compositions for targeted release of molecules from nanoscale carriers

The Regents of the University of California · Granted Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted